Skip to main navigation
Theratechnologies Inc. Theratechnologies Inc.

    About

  • About
    • About Us
    • Board of Directors
    • Leadership Team
    • Scientific Consultants & Advisors
    • Awards
  • Medicines & Pipeline

  • Medicines & Pipeline
    • Medicines
      • Trogarzo®
      • EGRIFTA SV®
    • Pipeline & Science
      • HIV
        • F8 in HIV-Associated Excess Abdominal Fat
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Hepatology
        • Tesamorelin for the Potential Treatment of NASH
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Oncology
        • SORT1+ Technology™
        • TH1902
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Expanded Access Policy
      • Grants/ISRs/IITs
  • IR Nav

  • Investors
    • Overview
    • News, Events & Presentations
      • Press Releases
      • Company Announcements
      • Events
      • Corporate Presentations
    • Stock Information
      • Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • SEDAR Filings
      • Financial Reports
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Investor Resources
      • Contact IR
      • FAQs
  • Corporate Responsibility

  • Corporate Responsibility
  • Careers

  • Careers
  • Contact Us

  • Contact Us
  • en
    • en
    • fr
  • btn Alerts

  • Sign up for Email Alerts

Social icons

Bio Details

Paul Lévesque

President and Chief Executive Officer

Paul Lévesque

Paul Lévesque was hired as President and CEO in March 2020. He came to Theratechnologies with 35 years’ experience in the research-based pharmaceutical industry including 28 years spent at Pfizer Inc.

Prior to joining Theratechnologies, Paul spent half of his professional career outside of Canada to take on various marketing and general management roles in Europe, Asia and the United States. His last assignment at Pfizer was to lead the Global Rare Disease Business Unit based in New York City. Along with the Head of Research and Development, he was responsible to drive the commercial success and the pipeline of the Unit.

Paul holds a BSc in biochemistry from Laval University and a Diploma in Management from McGill University.

    Headquarters

    Theratechnologies inc.
    2015 Peel Street, 11th Floor
    Montréal, Québec
    Canada H3A 1T8
    Phone: 514 336-7800
    Fax: 514 331-9691

    European Headquarters

    Theratechnologies Europe Limited
    2 Hume Street, 4th floor
    Dublin 2
    Ireland D02 DV24
    Phone: +353 1 215 0650
    europe@theratech.com

    Investor Relations

    Elif McDonald
    Senior Director, Investor Relations
    Phone: +1-438-315-8563
    ir@theratech.com

    US Headquarters

    Theratechnologies U.S., Inc.
    101 Hudson Street
    21st Floor
    Jersey City, New Jersey 07302

    Main Nav

    • Home
    • About
    • Medicines & Pipeline
    • Investors
    • Corporate Responsibility
    • Careers
    • Contact Us
    ©2023 - Theratechnologies Inc.

    Legal Nav

    • Terms of Use
    • Privacy

    Search

    Theratechnologies